Analyst Price Targets — VIR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 11, 2026 11:24 am | — | Morgan Stanley | $27.00 | $8.25 | TheFly | Vir Biotechnology price target raised to $27 from $23 at Morgan Stanley |
| May 8, 2026 1:28 pm | — | Morgan Stanley | $23.00 | $9.38 | TheFly | Vir Biotechnology price target lowered to $23 from $24 at Morgan Stanley |
| March 4, 2026 11:41 am | Patrick Trucchio | H.C. Wainwright | $20.00 | $9.13 | StreetInsider | Vir Biotechnology (VIR) PT Raised to $20 at H.C. Wainwright |
| February 26, 2026 6:07 pm | Roanna Ruiz | Leerink Partners | $20.00 | $9.33 | StreetInsider | Vir Biotechnology (VIR) PT Raised to $20 at Leerink Partners |
| February 24, 2026 7:22 pm | — | Barclays | $30.00 | $9.49 | TheFly | Vir Biotechnology price target raised to $30 from $26 at Barclays |
| February 24, 2026 1:02 pm | Cory Kasimov | Evercore ISI | $18.00 | $9.70 | TheFly | Vir Biotechnology price target raised to $18 from $12 at Evercore ISI |
| February 24, 2026 12:05 pm | Joseph Stringer | Needham | $18.00 | $9.64 | StreetInsider | Vir Biotechnology (VIR) PT Raised to $18 at Needham |
| February 24, 2026 11:49 am | Michael Ulz | Morgan Stanley | $24.00 | $7.43 | TheFly | Vir Biotechnology price target raised to $24 from $20 at Morgan Stanley |
| February 24, 2026 11:05 am | Sean McCutcheon | Raymond James | $19.00 | $9.69 | StreetInsider | Raymond James Upgrades Vir Biotechnology (VIR) to Strong Buy |
| February 17, 2026 11:36 am | — | Barclays | $26.00 | $7.47 | TheFly | Vir Biotechnology price target raised to $26 from $24 at Barclays |
Latest News for VIR
Vir Biotechnology is entering a catalyst-rich period with key clinical trial readouts from the ECLIPSE program in hepatitis delta plus updates from its T-cell engagers in oncology indications. VIR has partnered with Astellas Pharma to develop VIR-5500, its masked PSMA-targeting T-cell engager for prostate cancer. Updated data from VIR-5818 are due in H2'26 and could include a further ~18 months of data.
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. “We are pleased to welcome Tim to Vir Biotechnology's Board of Directors at a pivotal moment for the company,” said Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, Vir Biotechnology. “Tim brings…
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta at the upcoming EASL Congress 2026 in Barcelona, Spain, May 27-30, 2026. Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with…
Vir Biotechnology develops immunology-based therapies for infectious diseases, backed by collaborations and a diversified research pipeline.
Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VIR.
U.S. House Trading
No House trades found for VIR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.